The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder
Objective: This study aimed to determine the oncological outcomes of mixed-grade tumors by comparing them with pure low-grade and high-grade tumors. Methods: We retrospectively reviewed the medical records of patients with primary non-muscle-invasive bladder cancer. Patients were categorized into t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2021-12-01
|
| Series: | Medeniyet Medical Journal |
| Subjects: | |
| Online Access: | https://medeniyetmedicaljournal.org/jvi.aspx?pdir=medeniyet&plng=eng&un=MEDJ-48447&look4= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544876354338816 |
|---|---|
| author | Meftun Culpan Ferhat Keser Ayberk İplikci Gözde Kır Gökhan Atış Asif Yıldırım |
| author_facet | Meftun Culpan Ferhat Keser Ayberk İplikci Gözde Kır Gökhan Atış Asif Yıldırım |
| author_sort | Meftun Culpan |
| collection | DOAJ |
| description | Objective: This study aimed to determine the oncological outcomes of mixed-grade tumors by comparing them with pure low-grade and high-grade tumors.
Methods: We retrospectively reviewed the medical records of patients with primary non-muscle-invasive bladder cancer. Patients were categorized into three groups according to the histological grade of their tumors: low-grade, mixed-grade, and high-grade. Clinicopathological characteristics and oncological outcomes, such as recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS), were compared between the three groups.
Results: A total of 369 patients (190 low, 40 mixed, and 139 high-grade) were included in our study, with a mean follow-up of 55.94±41.73 months. Patients with mixed-grade tumors had lower rates of pT1 stage diseases than those with high-grade tumors (42.5% vs. 64.0%, respectively) and higher rates than those with low-grade tumors (14.7% vs. 42.5%, respectively) (p=0.001). There was no significant difference in RFS between low-, mixed-, and high-grade tumor patients (p=0.887). Patients with mixed-grade tumors had worse PFS and CSS outcomes than those with low-grade tumors (199.84±23.22 vs. 214.94±15.92 for PFS and 202.07±19.86 vs. 233.61±9.84 for CSS, respectively) and better PFS and CSS outcomes than those with highgrade tumors (199.84±23.22 vs. 163.28±16.18 for PFS and 202.07±19.86 vs. 180.81±15.89 for CSS, respectively), although these comparisons were not statistically significant.
Conclusions: Patients with mixed-grade tumors had worse PFS and CSS outcomes than patients with low-grade tumors and better PFS and CSS outcomes than patients with high-grade tumors, although these comparisons were not statistically significant. Our results should be verified by future studies. |
| format | Article |
| id | doaj-art-2c08287086bf4d80ad60d24bca330ad5 |
| institution | Kabale University |
| issn | 2149-2042 2149-4606 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Medeniyet Medical Journal |
| spelling | doaj-art-2c08287086bf4d80ad60d24bca330ad52025-02-03T08:56:15ZengGalenos Publishing HouseMedeniyet Medical Journal2149-20422149-46062021-12-0136431031710.4274/MMJ.galenos.2021.48447The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the BladderMeftun Culpan0https://orcid.org/0000-0001-8573-1192Ferhat Keser1https://orcid.org/0000-0002-2803-6481Ayberk İplikci2https://orcid.org/0000-0002-5822-7799Gözde Kır3https://orcid.org/0000-0003-1933-9824Gökhan Atış4https://orcid.org/0000-0002-9065-6104Asif Yıldırım5https://orcid.org/0000-0002-3386-971XIstanbul Medeniyet University Faculty of Medicine, Department of Urology, Istanbul, TurkeyIstanbul Medeniyet University Faculty of Medicine, Department of Urology, Istanbul, TurkeyIstanbul Medeniyet University Faculty of Medicine, Department of Urology, Istanbul, TurkeyIstanbul Medeniyet University Faculty of Medicine, Department of Pathology, Istanbul, TurkeyIstanbul Medeniyet University Faculty of Medicine, Department of Urology, Istanbul, TurkeyIstanbul Medeniyet University Faculty of Medicine, Department of Urology, Istanbul, TurkeyObjective: This study aimed to determine the oncological outcomes of mixed-grade tumors by comparing them with pure low-grade and high-grade tumors. Methods: We retrospectively reviewed the medical records of patients with primary non-muscle-invasive bladder cancer. Patients were categorized into three groups according to the histological grade of their tumors: low-grade, mixed-grade, and high-grade. Clinicopathological characteristics and oncological outcomes, such as recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS), were compared between the three groups. Results: A total of 369 patients (190 low, 40 mixed, and 139 high-grade) were included in our study, with a mean follow-up of 55.94±41.73 months. Patients with mixed-grade tumors had lower rates of pT1 stage diseases than those with high-grade tumors (42.5% vs. 64.0%, respectively) and higher rates than those with low-grade tumors (14.7% vs. 42.5%, respectively) (p=0.001). There was no significant difference in RFS between low-, mixed-, and high-grade tumor patients (p=0.887). Patients with mixed-grade tumors had worse PFS and CSS outcomes than those with low-grade tumors (199.84±23.22 vs. 214.94±15.92 for PFS and 202.07±19.86 vs. 233.61±9.84 for CSS, respectively) and better PFS and CSS outcomes than those with highgrade tumors (199.84±23.22 vs. 163.28±16.18 for PFS and 202.07±19.86 vs. 180.81±15.89 for CSS, respectively), although these comparisons were not statistically significant. Conclusions: Patients with mixed-grade tumors had worse PFS and CSS outcomes than patients with low-grade tumors and better PFS and CSS outcomes than patients with high-grade tumors, although these comparisons were not statistically significant. Our results should be verified by future studies.https://medeniyetmedicaljournal.org/jvi.aspx?pdir=medeniyet&plng=eng&un=MEDJ-48447&look4=bladder cancerheterogeneityhistologic gradeprogressionrecurrence |
| spellingShingle | Meftun Culpan Ferhat Keser Ayberk İplikci Gözde Kır Gökhan Atış Asif Yıldırım The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder Medeniyet Medical Journal bladder cancer heterogeneity histologic grade progression recurrence |
| title | The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder |
| title_full | The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder |
| title_fullStr | The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder |
| title_full_unstemmed | The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder |
| title_short | The Clinical Impact of Tumor Grade Heterogeneity in Nonmuscle- invasive Urothelial Carcinoma of the Bladder |
| title_sort | clinical impact of tumor grade heterogeneity in nonmuscle invasive urothelial carcinoma of the bladder |
| topic | bladder cancer heterogeneity histologic grade progression recurrence |
| url | https://medeniyetmedicaljournal.org/jvi.aspx?pdir=medeniyet&plng=eng&un=MEDJ-48447&look4= |
| work_keys_str_mv | AT meftunculpan theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT ferhatkeser theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT ayberkiplikci theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT gozdekır theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT gokhanatıs theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT asifyıldırım theclinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT meftunculpan clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT ferhatkeser clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT ayberkiplikci clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT gozdekır clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT gokhanatıs clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder AT asifyıldırım clinicalimpactoftumorgradeheterogeneityinnonmuscleinvasiveurothelialcarcinomaofthebladder |